Press release

Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an individual who has demonstrated an enterprising approach to developing and delivering enterprise and entrepreneurial learning and skills, inspiring students and enabling them to realise their enterprise potential. The Academic to Entrepreneur […]

Our CEO Caroline Barelle was interviewed by Scottish Business News Network. In her interview, Caroline discusses the journey of starting up Elasmogen and provides an insight into the ups and downs of those early days alongside a glimpse into where Elasmogen is now and the future of the company. Read the full interview here Caroline […]

£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen, an SME focused on the development of next generation biologics, announced today that they have been awarded […]

17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising Stars: Extraordinary Talent (2017)” category at last night’s Scotland’s Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland’s top Life […]

Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and business leaders have been shortlisted for the prestigious Scottish Life Sciences Awards 2018. Read more here

Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets   Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop […]

Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics   Thursday, 16 March 2017: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and […]

BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew Porter at the University of Aberdeen. The company is developing new medicines based on the discovery of certain antibody-like molecules found in sharks. IMPACT SUMMARY University of Aberdeen researchers Dr Caroline Barelle and […]

Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain independent and celebrate innovation across the UK life sciences industry and recognise achievements from emerging to late stage R&D companies, as well as life sciences investors. A judging […]